Fibrotic Disease Activity in Cardiopulmonary Disorders Using 18F-Fibroblast Activation Protein Inhibitor (18F-FAPI-74) PET/CT Imaging

A phase 3 trial registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 210 participants.

Also called NCT07613099

  • Study
  • In this atlas

Overview

Design
Interventional study; non-randomized; no masking; primary purpose diagnostic
Phase
Phase 3
Enrolled
  • 210 participants (planned count) (from the registry)
Sponsor
Registry
  • NCT NCT07613099
Started
(actual) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
United States (from the registry)
Registry status
  • Recruiting (from the registry)

Technical summary

Registry record NCT07613099. Non-randomized; no masking; primary purpose diagnostic. Start 2026-09-18 (actual); primary completion 2031-05-26 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Fibrotic Disease Activity in Cardiopulmonary Disorders Using 18F-Fibroblast Activation Protein Inhibitor (18F-FAPI-74) PET/CT Imaging
Condition
Allogeneic Stem Cell Transplantation
Condition
Lung Allograft Transplantation
Condition
Interstitial Lung Disease
Condition
Acute Lung Injury
Condition
Pulmonary Arterial Hypertension
Condition
Cardiovascular Diseases
Intervention (Drug)
[18F]FAPI-74
Intervention (Diagnostic test)
18F-FAPI-74 PET/CT Imaging
Lead sponsor
National Heart, Lung, and Blood Institute (NHLBI) (class: US National Institutes of Health)

Record details

Record id
cardio:ct-nct07613099
Content hash
d08c2dced2e60a06396e38785415f8d6e01041056042d346e96026c91a7a8e1b